Edition:
United Kingdom

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

18.38USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$18.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
175,304
52-wk High
$25.93
52-wk Low
$8.10

Chart for

About

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophi... (more)

Overall

Beta: --
Market Cap(Mil.): $557.18
Shares Outstanding(Mil.): 26.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics

* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​ Source text: (http://bit.ly/2CZEeZD) Further company coverage:

10 Jan 2018

BRIEF-Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr

* Voyager Therapeutics announces pricing of public offering of common stock

08 Nov 2017

BRIEF-Voyager Therapeutics announces proposed offering of common stock

* Voyager Therapeutics announces proposed offering of common stock

06 Nov 2017

BRIEF-Voyager Therapeutics reports Q3 GAAP loss per share $0.89

* Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights

02 Nov 2017

BRIEF-Voyager Therapeutics reports positive results from ongoing trial for advanced parkinson’s disease

* Voyager Therapeutics announces positive results from ongoing Phase 1b trial of VY-AADC01 for advanced parkinson’s disease

06 Sep 2017

Earnings vs. Estimates